High BMI Associated With Improved Survival in DLBCL

According to the findings of a retrospective analysis of over 2,500 US military veterans diagnosed with diffuse large B-cell lymphoma (DLBCL) between 1998 and 2008, contrary to most findings and contrary to the party line regarding obesity and cancer, being overweight or obese at time of diagnosis correlated with improved survival.

This retrospective cohort study was published recently in the Journal of Clinical Oncology.

BMI at time of diagnosis studied

Researchers from the St. Louis Veterans Affairs Medical Center sought to determine what, if any, the association might be between body mass index (BMI) at time of diagnosis and overall survival.

Their conclusion? "Being overweight or obese at the time of DLBCL diagnosis is associated with improved overall survival."

Among the cohort, the mean age at diagnosis was 68 and the percentage of patients who were considered to be overweight or obese was 64. When researchers set them against other MBI groups, they found that obese patients tended to be much younger, have fewer 'B' symptoms, and tended to be diagnosed early and therefore have stage I or II disease.

When they were compared to patients considered to have a normal BMI, they found a lower mortality for the overweight/obese group.

Source: JCO

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap